The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome

Journal of Interventional Cardiology

Volumn 21, Issue SUPPL. 1, 2008, Pages

  Gurbel, Paul A ^a,b   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b Off Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PRT 128; PURINERGIC RECEPTOR BLOCKING AGENT; SCH 530348; THROMBIN INHIBITOR; THROMBOXANE A2; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY STENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MUSCLE NECROSIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 56849102688     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00408.x     Document Type: Conference Paper

References (48)

1. Jackson SP. The growing complexity of platelet aggregation. Blood 2007 109 : 5087 5095.
2. Tantry US, Etherington E, Bliden KP, et al. Antiplatelet therapies: Current strategies and future trends. Future Cardiol 2006 2 : 343 366.
3. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005 46 : 1820 1826.
4. Whincup PH, Danesh J, Walker M, et al. von Willebrand factor and coronary heart disease: Prospective study and meta-analysis. Eur Heart J 2002 23 : 1764 1770.
5. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: Prospective study and meta-analysis. Circulation 2001 103 : 2323 2327.
6. Danesh J, Lewington S, Thompson SG, et al. for Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005 294 : 1799 1809.
7. Gurbel PA, Bliden KP, Kreutz KP, et al. Relation of platelet-fibrin clot strength, platelet reactivity, inflammation and growth factor release to thrombotic risk in patients undergoing stenting: A biomarker profile correlating vulnerable blood to vulnerable patient. J Thromb Haemost 2007 5 (Suppl. 2 P-W-683.
8. Tantry US, Bliden KP, Kreutz RP, et al. Transition to an unstable coronary syndrome is marked by hypercoagulability, platelet activation, heightened platelet reactivity, and inflammation: Results of the Thrombotic RIsk Progression (TRIP) study. J Am Coll Cardiol 2007 49 : 196A.
9. Gurbel PA, Bliden KP, Hayes KM, et al. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004 2 : 535 545.
10. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 109 : 3171 3175.
11. Gurbel PA, Bliden KP, DiChiara J, et al. The prediction of ischemic events after percutaneous coronary intervention by platelet reactivity to adenosine diphosphate: First evidence for an oral antiplatelet therapeutic target determined by an ex vivo test of platelet function. Circulation 2007 116 : 2372.
12. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel Loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005 111 : 1153 1159.
13. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006 4 : 542 549.
14. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007 50 : 1822 1834.
15. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003 59 : 295 302.
16. Gurbel PA, Bliden KP, Samara W, et al. The Clopidogrel Resistance and Stent Thrombosis (CREST) study. J Am Coll Cardiol 2005 46 : 1827 1832.
17. Buonamici P, Marcucci R, Miglironi A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007 49 : 2312 2317.
18. Awtry EH, Loscalzo J. Aspirin. Circulation 2000 101 : 1206 1218.
19. King SB III., Smith SC Jr., Hirshfeld JW Jr., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008 51 : 172 209.
20. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007 115 : 3156 3164.
21. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007 56 : 3014 3019.
22. Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006 98 : 1156 1159.
23. Foussas SG, Zairis MN, Patsourakos NG, et al. The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. Am Heart J 2007 154 : 676 681.
24. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 2006 19 : 439 448.
25. CAPRIE Streeing Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 348 : 1329 1339.
26. Sabatine MS, Cannon CP, Gibson CM, et al., for CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 352 : 1179 1189.
27. Sabatine MS, Cannon CP, Gibson CM, et al., for Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005 294 : 1224 1232.
28. Gurbel PA, Tantry US. The role of clopidogrel in cardiovascular diseases. Pol Arch Med Wewn 2007 117 : 207 209.
29. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 357 : 2001 2015.
30. Ahn H-S, Chackalamannil S, Boykow G, et al. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis, and inflammatory diseases. Curr Pharm Design 2003 9 : 2349 2365.
31. Moliterno DJ, Jennings L, Becker RC, et al., for TRA-PCI Investigators. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Presented at American College of Cardiology Meetings, 2007.
32. Topol EJ, Byzova TV, Plow EF. Platelet GP IIb-IIIa blockers. Lancet 1999 353 : 227 231.
33. Januzzi JL, Cannon CP, Theroux P, et al. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: Risk stratification and therapeutic intervention. Am Heart J 2003 146 : 764 774.
34. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991 88 : 10624 10628.
35. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GP IIb-IIIa antagonists. J Thromb Haemost 2004 2 : 1118 1126.
36. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997 349 : 1429 1435.
37. Roffi M, Moliterno DJ, Meier B, et al., for TARGET Investigators. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002 105 : 2730 2736.
38. Morrow DA, Cannon CP, Rifai N, et al., for TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial. JAMA 2001 286 : 2405 2012.
39. Kandzari DE, Berger PB, Kastrati A, et al., for ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004 44 : 2133 2136.
40. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006 295 : 1531 1538.
41. Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: Results of the ISAR-REACT 2 randomized trial. Eur Heart J 2008 29 : 455 461.
42. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin in biomarker negative patients with stable and unstable angina undergoing PCI; ISAR-REACT 3 (Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment 3) trial. Presented at American College of Cardiology 2008 Scientific Sessions /i2 Summit-SCAI Annual Meeting, Chicago, 2008.
43. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: Results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006 48 : 2186 2191.
44. Gurbel PA, Bliden KP, Kreutz RP, et al. Superior effect of eptifibatide added to clopidogrel on biomarker expression detected by fluorokine multi-analyte profiling in patients undergoing elective PCI. Presented at International Society of Thrombosis and Hemostasis Society Meeting 2007, Geneva. P-S-343.
45. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 289 : 853 863.
46. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 355 : 2203 2216.
47. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Lancet 2007 369 : 907 919.
48. Gurbel PA, Bliden KP, DiChiara J, et al. Bivalirudin with and without eptifibatide for elective stenting: A pharmacodynamic study of platelet reactivity in relation to the occurrence of periprocedural myocardial infarction. Circulation 2007 116 : 2364.